Alkermes (ALKS) Net Income towards Common Stockholders Growth (1y) (2011 - 2025)
Alkermes (ALKS) Net Income towards Common Stockholders Growth (1y) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 68.18% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -0.17% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -388.62% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -14.68% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 105.80% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 2,405.06% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -14.93% |
| 10 | Alkermes | 8.78 Bn | 8.26 Bn | 331.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 219,447.73% |
| Dec 31, 2024 | 100.11% |
| Sep 30, 2024 | 98.94% |
| Jun 30, 2024 | 92.15% |
| Mar 31, 2024 | 94.20% |
| Dec 31, 2023 | -146.58% |
| Sep 30, 2023 | 29.12% |
| Jun 30, 2023 | -39.49% |
| Mar 31, 2023 | -1.72% |
| Dec 31, 2022 | -35.99% |
| Sep 30, 2022 | -120.69% |
| Jun 30, 2022 | -1,374.79% |
| Mar 31, 2022 | -60.15% |
| Dec 31, 2021 | 562.69% |
| Sep 30, 2021 | -21,532.84% |
| Jun 30, 2021 | 108.03% |
| Mar 31, 2021 | 42.00% |
| Dec 31, 2020 | -1,376.00% |
| Sep 30, 2020 | 99.75% |
| Jun 30, 2020 | 29.91% |